Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma

BACKGROUND: This phase I/II trial evaluated the maximum tolerated dose (MTD) and pharmacokinetics of afatinib plus temozolomide as well as the efficacy and safety of afatinib as monotherapy (A) or with temozolomide (AT) vs temozolomide monotherapy (T) in patients with recurrent glioblastoma (GBM). M...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Reardon, David A., Nabors, Louis B., Mason, Warren P., Perry, James R., Shapiro, William, Kavan, Petr, Mathieu, David, Phuphanich, Surasak, Cseh, Agnieszka, Fu, Yali, Cong, Julie, Wind, Sven, Eisenstat, David D.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2015
Témata:
Clinical Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4483093/
https://ncbi.nlm.nih.gov/pubmed/25140039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou160
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky